Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16647590 | 1.00 | TYMP (0.31) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL15837360 | 0.96 | TYMP (0.32) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL17515661 | 0.95 | TYMP (0.32) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL15833294 | 0.94 | TYMP (0.31) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL15837386 | 0.93 | TYMP (0.30) | TYMP | |
| SCHEMBL15833153 | 0.93 | NT5E (0.33) | TYMPADORA3ADORA2AADORA1 | |
| SCHEMBL17357570 | 0.93 | NT5E (0.33) | TYMPADORA3ADORA2AADORA1 | |
| SCHEMBL16639990 | 0.91 | TYMP (0.31) | TYMP | |
| SCHEMBL15833230 | 0.90 | TYMP (0.33) | TYMPADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL25524866 | 0.90 | TYMP (0.33) | TYMPADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2018-03-22 | — | — | US | disclosed |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2018-02-15 | — | — | US | disclosed |
| US-9862743-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9815864-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-9603863-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20170037075-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2016-01-21 | — | — | US | disclosed |
| WO-2015200205-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200219-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-04-16 | — | — | US | disclosed |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-01-08 | — | — | US | disclosed |
| WO-2014100505-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TYMP 14/4885ADORA3 97/4885ADORA2A 71/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TYMP 14/4885ADORA3 97/4885ADORA2A 71/4885 |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TYMP 14/4885ADORA3 97/4885ADORA2A 71/4885 |
| US-20170037077-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TYMP 14/4885ADORA3 97/4885ADORA2A 71/4885 |
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | TYMP 3/4885ADORA3 83/4885ADORA2A 78/4885 |
| US-20180079774-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TYMP 32/4885ADORA3 53/4885ADORA2A 47/4885 |
| US-20180044369-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | TYMP 23/4885ADORA3 73/4885ADORA2A 57/4885 |
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | TYMP 3/4885ADORA3 83/4885ADORA2A 78/4885 |
| US-20170037075-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TYMP 14/4885ADORA3 97/4885ADORA2A 71/4885 |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TYMP 10/4885ADORA3 79/4885ADORA2A 71/4885 |
| US-20150105341-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NUDT1 | TYMP 23/4885ADORA3 73/4885ADORA2A 57/4885 |
| US-20160016987-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | TYMP 14/4885ADORA3 97/4885ADORA2A 71/4885 |
| US-20150366887-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TYMP 10/4885ADORA3 79/4885ADORA2A 71/4885 |
| US-20150011497-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | TYMP 32/4885ADORA3 53/4885ADORA2A 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.